Leading ADC Targets in Oncology: Signaling Mechanisms and Therapeutic Advances
Antibody–drug conjugates (ADCs) use tumor cell-surface antigens to achieve antibody recognition and payload delivery. HER2, TROP2, Nectin-4, FRα, and c-Met have received substantial clinical validation, while HER3, B7-H3, CLDN18.2, and DLL3 continue to enter ADC development pipelines. The ...
危险品化学品经营许可证（带存储）